Alitair Pharmaceuticals has received Orphan Drug Designation from the FDA for Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties. Erdosteine is currently approved for the treatment of COPD and chronic bronchitis in 50 countries outside of the U.S. Because the company currently has an open IND for Erdosteine for a different indication, it will be able to go directly into the clinic after a pre-IND meeting w...